Sign in
Taking people in United StatesNo phase

Studies how HeartMate 3 pump data relates to patient health and quality of life

Observes heart pump data and health in adults with advanced heart failure.

Key facts

Who runs it
International Consortium of Circulatory Assist Clinicians
Where
Charleston, Chicago, Gainesville, Kansas City, Rochester, Salt Lake City, and San Francisco, United StatesSee the 7 sites
Trial code
Registry title
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
Status
Recruiting
People taking part
150 people, planned
Started
27 Oct 2023
Expected to end
30 Dec 2026
Type of study
Observational, 7 groups
Treatments tested
  • HeartMate 3 (R) left ventricular assist device
Record updated
16 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are scheduled to get a HeartMate 3 heart pump (left ventricular assist device).

Age
18 years or older (up to 100 years)
Sex
All sexes can join.

Main reasons for not taking part

  • Under 18 years of age
  • Scheduled for a heart pump that is not a HeartMate 3 device

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • 18 years of age or older
  • Scheduled Heartmate 3 ® dLVAD implantation

Who cannot take part

  • <18 years of age
  • Scheduled for dLVAD that is NOT a Heartmate 3 (R) device

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Where in United States

  • MUSCCharleston, United StatesContact: Sarah E Schroeder, PhD MSN RNNo longer taking part
  • University of ChicagoChicago, United StatesContact: Krystina ChickerilloTaking people
  • University of FloridaGainesville, United StatesContact: Sara GeigerTaking people
  • University of Kansas Medical CenterKansas City, United StatesContact: Sarah E Schroeder, PhD MSN RNNo longer taking part
  • Mayo Clinic - RochesterRochester, United StatesContact: Sarah Schettle, PATaking people
  • University of UtahSalt Lake City, United StatesContact: Sarah E Schroeder, PhD MSN RNNo longer taking part
  • UCSFSan Francisco, United StatesContact: Sylvie BaudartTaking people

About the trial

What the trial wants to find out

Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation. Despite the decreasing size of the newest generation devices leading to a lessened occurrence of adverse events, bleeding and infection still remain a concern for clinicians, as well as a general lack of predictability towards adverse events in individuals with a dLVAD in place. There is a lack of description in the literature currently, regarding the interface between what the pump data provides and what is seen in clinical practice. There also is little known about the effects of what is provided in the pump data, in correlation to quality-of-life following dLVAD implantation.

Read full original descriptionShow less

Therefore, the purpose of this study is to prospectively analyze normal and abnormal pump data through pump operations such as suction events, low flow alarms as well as other adventitious alarms, PI events and power cable disconnects greater than 20 seconds, from the HeartMate 3 ® dLVAD in order to clinically correlate this data to quality of life, frailty and other various medical conditions and adverse events as defined by the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs). This will be achieved through two aims: 1) Evaluate the effectiveness of dLVAD pump operations data on clinical practice application (quality of life, frailty and various medical conditions, and adverse events such as GIB, RHF, infection, hypertension, arrhythmias and stroke); and 2) Evaluate correlations and relationships of longitudinal normal and abnormal dLVAD pump operations data, to demographic and clinical variables. This study is the first study to evaluate HeartMate 3 ® dLVAD pump operations data over time for effectiveness in the clinical practice.

The 7 groups in the trial

  • Mayo Clinic

    Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.

    Treatment: HeartMate 3 (R) left ventricular assist device

  • University of Florida

    Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.

    Treatment: HeartMate 3 (R) left ventricular assist device

  • University of Utah

    Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.

    Treatment: HeartMate 3 (R) left ventricular assist device

  • University of California, San Francisco

    Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.

    Treatment: HeartMate 3 (R) left ventricular assist device

  • University of Chicago

    Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.

    Treatment: HeartMate 3 (R) left ventricular assist device

  • University of Kansas Medical System

    Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.

    Treatment: HeartMate 3 (R) left ventricular assist device

  • Medical University of South Carolina

    Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.

    Treatment: HeartMate 3 (R) left ventricular assist device

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
Plain-language title
Studies how HeartMate 3 pump data relates to patient health and quality of lifeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06039176, who can take part
Record updated
16 December 2025